{"disease":{"id":"refractory-or-relapsed-aggressive-r-r-b-nhl-with-huge-tumor-burden","name":"refractory or relapsed aggressive r r b nhl with huge tumor burden"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04553393","title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}